We serve Chemical Name:C-Thiazol-4-Yl-Methylamine Hydrochloride CAS:117043-86-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:C-Thiazol-4-Yl-Methylamine Hydrochloride
CAS.NO:117043-86-4
Synonyms:THIAZOLE-4-METHYLAMINE HCL;4-Thiazolemethanamine, hydrochloride (1:1);thiazol-4-ylmethanamine hydrochloride;1-(1,3-Thiazol-4-yl)methanamine hydrochloride (1:1);C-Thiazol-4-yl-methylamin,Hydrochlorid;THIAZOL-4-YLMETHYLAMINE HCL;BESTIPHARMA 501-183;C-THIAZOL-4-YL-METHYLAMINE HYDROCHLORIDE;C-thiazol-4-yl-methylamine,monohydrochloride;4-aminomethylthiazole hydrochloride
Molecular Formula:C4H7ClN2S
Molecular Weight:150.630
HS Code:2934100090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:67.15000
Exact Mass:150.001846
LogP:2.10410
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like THIAZOLE-4-METHYLAMINE HCL chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-aminomethylthiazole hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,thiazol-4-ylmethanamine hydrochloride Use and application,4-aminomethylthiazole hydrochloride technical grade,usp/ep/jp grade.
Related News: Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Holantogenin manufacturers By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%. 4,4a,5,5,6,7-hexachlorooctahydro-1,3,4,6-(epiethane[1,1,2,2]tetrayl)cyclopenta[cd]pentalen-3(1H)-amine suppliers providing support for flexible, cross-sector training programmes to encourage more movement and collaboration between academia, industry and the charity sector 4,4′-(4-butyl-3,5-dioxo-pyrazolidine-1,2-diyl)-bis-benzenesulfonic acid vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Holantogenin manufacturers By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%. 4,4a,5,5,6,7-hexachlorooctahydro-1,3,4,6-(epiethane[1,1,2,2]tetrayl)cyclopenta[cd]pentalen-3(1H)-amine suppliers providing support for flexible, cross-sector training programmes to encourage more movement and collaboration between academia, industry and the charity sector 4,4′-(4-butyl-3,5-dioxo-pyrazolidine-1,2-diyl)-bis-benzenesulfonic acid vendor & factory.
